LANGUAGE
KOREAN
ENGLISH
LOCATION
COMPANY
R&D
R&D Institute
GMP Center
Clinical Development Status
Publications
PRODUCTS
1st Generation
Overview
CARTISTEM
®
PNEUMOSTEM
®
2nd Generation
Overview
SMUP-IA-01
SMUP-IV-01
R&D Inquiries
BUSINESS
CDMO
Quality System
CDMO Service
Quality Control
Global CDMO
CDMO Inquiries
CELLTREE Cord Blood Bank
MOVITA Nutritional Supplements
IR
Stock Information
Disclosure
Financial Information
IR Inquiries
PR
MEDIPOST on Media
Corporate Brochure
CONTACT US
Customer Center
R&D Inquiries
CDMO Inquiries
IR Inquiries
MEDIPOST on Media
Corporate Brochure
MEDIPOST on Media
All
MEDIPOST
11
STEM CELL THERAPEUTIC
108
CDMO
4
CORD BLOOD BANK
10
MEDIPOST Submits Application for Product Authorization Amendment to Add Ankle In…
2023/12/27
MEDIPOST Selected for a Government-Supported R&D Project Worth KRW 13 billi…
2023/10/04
MEDIPOST’s CARTISEM®, Umbilical Cord Blood-derived Stem Cell Transplant Surgery…
2023/05/02
MEDIPOST Treats First Subject with CARTISTEM® in Japan Phase 3 Clinical Trial, A…
2023/01/16
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration…
2022/12/01
Medipost to launch a CDMO business for cell and gene therapy products in Korea b…
2022/10/17
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy
2022/10/07
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJS…
2022/07/18
VIEW MORE NEWS
MEDIPOST on Media
Corporate Brochure
Menu
